会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS
    • 含NICOTINE的药物组合物
    • WO2011139684A2
    • 2011-11-10
    • PCT/US2011/033928
    • 2011-04-26
    • NICONOVUM USA, INC.BRINKLEY, Paul AndrewBORSCHKE, August Joseph
    • BRINKLEY, Paul AndrewBORSCHKE, August Joseph
    • A61K9/00
    • A61K9/0056A61K9/0058A61K9/006A61K31/19A61K31/465A61K31/787A61M15/009A61M15/0091
    • A composition intended to be employed for therapeutic purposes incorporates a source of nicotine and at least one levulinate moiety. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The levulinate moiety can have the form of an acid (e.g., levulinic acid), a levulinate salt (e.g., sodium levulinate), or an ester of levulinic acid (e.g., methyl levulinate or ethyl levulinate). The composition can incorporate nicotine and levulinic acid in a salt form (e.g., nicotine levulinate). The composition can be composed of at least two forms of nicotine, and one of the forms of nicotine is in the form of nicotine levulinate. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy.
    • 旨在用于治疗目的的组合物包含尼古丁来源和至少一个乳酸部分。 尼古丁的代表性形式包括游离碱(例如,作为尼古丁和微晶纤维素的混合物),尼古丁盐(例如,作为烟碱酒石酸氢盐)或尼古丁polacrilex。 树脂部分可以具有酸(例如乙酰丙酸),乙酰丙酸盐(例如乙酰丙酸钠)或乙酰丙酸(例如乙酰丙酸甲酯或乙酰丙酸乙酯)的形式。 组合物可以加入盐形式的尼古丁和乙酰丙酸(例如,乙酰丙酸烟碱)。 组合物可以由至少两种形式的尼古丁组成,其中一种形式的尼古丁是烟酰胺酸盐的形式。 该组合物可用于治疗中枢神经系统疾病和疾病,以及作为尼古丁替代疗法。
    • 8. 发明申请
    • NICOTINE-CONTAINING PHARMACEUTICAL COMPOSITIONS
    • 含NICOTINE的药物组合物
    • WO2011139684A3
    • 2012-03-08
    • PCT/US2011033928
    • 2011-04-26
    • NICONOVUM USA INCBRINKLEY PAUL ANDREWBORSCHKE AUGUST JOSEPH
    • BRINKLEY PAUL ANDREWBORSCHKE AUGUST JOSEPH
    • A61K9/00A61K31/19A61K31/465A61M15/00B65D83/52
    • A61K9/0056A61K9/0058A61K9/006A61K31/19A61K31/465A61K31/787A61M15/009A61M15/0091
    • A composition intended to be employed for therapeutic purposes incorporates a source of nicotine and at least one levulinate moiety. Representative forms of nicotine include free base (e.g., as a mixture of nicotine and microcrystalline cellulose), a nicotine salt (e.g., as nicotine bitartrate) or nicotine polacrilex. The levulinate moiety can have the form of an acid (e.g., levulinic acid), a levulinate salt (e.g., sodium levulinate), or an ester of levulinic acid (e.g., methyl levulinate or ethyl levulinate). The composition can incorporate nicotine and levulinic acid in a salt form (e.g., nicotine levulinate). The composition can be composed of at least two forms of nicotine, and one of the forms of nicotine is in the form of nicotine levulinate. The composition is useful for treatment of central nervous system conditions, diseases, and disorders, and as a nicotine replacement therapy.
    • 旨在用于治疗目的的组合物包含尼古丁来源和至少一个乳酸部分。 尼古丁的代表性形式包括游离碱(例如,作为尼古丁和微晶纤维素的混合物),尼古丁盐(例如,作为烟碱酒石酸氢盐)或尼古丁polacrilex。 乙酰丙酸部分可以具有酸(例如乙酰丙酸),乙酰丙酸盐(例如乙酰丙酸钠)或乙酰丙酸(例如乙酰丙酸甲酯或乙酰丙酸乙酯)的酯的形式。 组合物可以加入盐形式的尼古丁和乙酰丙酸(例如,乙酰丙酸烟碱)。 组合物可以由至少两种形式的尼古丁组成,其中一种形式的尼古丁是烟酰胺酸盐的形式。 该组合物可用于治疗中枢神经系统疾病和疾病,以及作为尼古丁替代疗法。